Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

Rahal, Rami, Frick, Mareike, Romero, Rodrigo, Korn, Joshua M, Kridel, Robert, Chun Chan, Fong, Meissner, Barbara, Bhang, Hyo-eun +22 more·2014·Nature Medicine

DOI 10.1038/nm.3435

Cited by (336)

Items 201–300 of 336

The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
Alberto Zamò, Michiel van den Brand, Fina Climent, Laurence de Leval, Stefan Dirnhofer, Lorenzo Leoncini, Siok‐Bian Ng, Sarah Lynn Ondrejka, Leticia Quintanilla‐Martínez, Lorinda A. Soma et al. · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression
Simona Gambino, Francesca Maria Quaglia, Marilisa Galasso, Chiara Cavallini, Roberto Chignola, Ornella Lovato, Luca Giacobazzi, Simone Caligola, Annalisa Adamo, Santosh Putta et al. · 2024 · Scientific Reports
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana Carvalho Santos, Marc Armengol, Miranda Fernández-Serrano, Alícia Sedó Mor, Joan Josep Bech‐Serra, Pedro Blecua et al. · 2021 · Clinical Cancer Research
TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs
Monika Vashisht, Huaibin Ge, Jessy John, Harlie A. McKelvey, Jingxin Chen, Zhangguo Chen, Jing Hong Wang · 2023 · Cell Death and Disease
Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
Asim Najmi, Neelaveni Thangavel, Anugeetha Thacheril Mohanan, Marwa M. Qadri, Mohammed Albratty, Safeena Eranhiyil Ashraf, Safaa Fathy Saleh, Maryam Nayeem, Syam Mohan · 2023 · Pharmaceuticals
Diagnostic, Prognostic, and Predictive Role of Next-Generation Sequencing in Mature Lymphoid Neoplasms
Graham W. Slack · 2023 · Surgical pathology clinics
Novel therapies for relapsed/refractory mantle cell lymphoma
Puja C. Arora, Craig Anthony Portell · 2017 · Best Practice & Research Clinical Haematology
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Edward Nabrinsky, Alexey Valeryevich Danilov, Paul Koller · 2021 · Current Hematologic Malignancy Reports
Estrogen Receptor β (ESR2) Transcriptome and Chromatin Binding in a Mantle Cell Lymphoma Tumor Model Reveal the Tumor-Suppressing Mechanisms of Estrogens
Dan Huang, Zhiqiang Huang, Rajitha Indukuri, Chandrashekar Bangalore Revanna, Mattias Berglund, Jiyu Guan, Konstantin Yakimchuk, Anastasios E. Damdimopoulos, Cecilia Williams, Sam Okret · 2022 · Cancers
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
Ciara Louise L. Freeman, Prasath Pararajalingam, Ling Jin, Sriram Balasubramanian, Aixiang Jiang, Wendan Xu, Michael Grau, Myroslav Zapukhlyak, Merrill Boyle, Brendan Paul Hodkinson et al. · 2022 · Leukemia
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma
Makhdum Ahmed, Elizabeth Lorence, Jeffrey Wang, Dayoung Jung, Liang Zhang, Krystle J. Nomie, Michael L. Wang · 2019 · Science Signaling
Molecular profiling and management of mantle cell lymphoma
Jia Ruan · 2019 · Hematology
Marginal Zone Lymphomas
Francesco Bertoni, Davide Rossi, Markus Raderer, Emanuele Zucca · 2020 · The Cancer Journal
Advances in Classification and Treatment of Non-Hodgkin Lymphoma
Simon A. Rule, Sophie Johns · 2020 · The Cancer Journal
Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma
Alberto Mussetti, Anita Ashok Kumar, Parastoo Bahrami Dahi, Miguel‐Angel Perales, Craig Steven Sauter · 2014 · Blood Reviews
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, Dalia Y. Moore, Lelisse T. Umeta, Lynette M. Smith, Elizabeth Ruby Lyden, Christopher Robert D'Angelo, Avyakta Kallam, Julie Marie Vose et al. · 2022 · International Journal of Molecular Sciences
Targeting protein kinase C in mantle cell lymphoma
Hilka Rauert‐Wunderlich, Martina Rudelius, German Ott, Andreas Rosenwald · 2016 · British Journal of Haematology
Bruton's tyrosine kinase inhibitors
Loïc Ysebaert, Anne‐Sophie Michallet · 2014 · Current Opinion in Oncology
Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells
Pascal Gélébart, May Eriksen Gjerstad, Susanne Benjaminsen, Jianhua Han, Ida Tveit Karlsen, Mireia Mayoral Safont, Calum Leitch, Zinayida Fandalyuk, Mihaela Lucia Popa, Lars Helgeland et al. · 2023 · Blood
Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance
Xiaoqing Sun, Caiqin Wang, Jianghua Cao, Jing Li, Gang Ma, Xianqiu Wu, Peng Sun, Yu Wang, Jiajia Huang, Robert Peter Gale et al. · 2024 · Journal of Advanced Research
First Report of FARSA in the Regulation of Cell Cycle and Survival in Mantle Cell Lymphoma Cells via PI3K-AKT and FOXO1-RAG1 Axes
Min Hua Feng, Kun Yang, Jia Wang, Guilan Li, Han Zhang · 2023 · International Journal of Molecular Sciences
miR‐17‐92 cluster‐BTG2 axis regulates B‐cell receptor signaling in mantle cell lymphoma
Yuka Kawaji‐Kanayama, Taku Tsukamoto, Masakazu Nakano, Yasuharu Tokuda, Hiroaki Nagata, Kentaro Mizuhara, Yoko Katsuragawa‐Taminishi, Reiko Isa, Takahiro Fujino, Yayoi Matsumura‐Kimoto et al. · 2023 · Cancer Science
Novel agents for mantle cell lymphoma: molecular rational and clinical data
Clémentine Sarkozy, Vincent Ribrag · 2020 · Expert Opinion on Investigational Drugs
MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway
Jingjing Yuan, Qing Zhang, Shengsheng Wu, Suran Yan, Ran Zhao, Yajuan Sun, Xiaoxu Tian, Keshu Zhou · 2021 · OncoTargets and Therapy
Biology of splenic and nodal marginal zone lymphomas
Valeria Spina, Afua A. Mensah, Alberto J. Arribas · 2021 · Annals of Lymphoma
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma
Jingjing Yuan, Qing Hua Zhang, Shengsheng Wu, Suran Yan, Ran Zhao, Yajuan Sun, Xiaoxu Tian, Keshu Zhou · 2021 · Experimental Hematology
Catalog of genetic progression of human cancers: non-Hodgkin lymphoma
Csaba Bödör, Lilla Reiniger · 2016 · Cancer and Metastasis Reviews
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Georg Lenz · 2017 · Journal of Clinical Oncology
Pathways towards indolent B-cell lymphoma — Etiology and therapeutic strategies
Michiel van den Brand, Blanca Scheijen, Corine J. Hess, J. Han van Krieken, Patricia J.T.A. Groenen · 2017 · Blood Reviews
New responsibilities for aged kinases in B‐lymphomas
Francesco Piazza, Sabrina Manni, Arash Arjomand, Andrea Visentin, Livio Trentin, Gianpietro Semenzato · 2019 · Hematological Oncology
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Nada Alsuhebany, Congshan Pan, Eileen Holovac, Brian Do, Ali McBride · 2023 · Blood and Lymphatic Cancer Targets and Therapy
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Patrick Nylund, Anna Nikkarinen, Sara Ek, Ingrid Cecilia Glimelius · 2024 · Frontiers in Immunology
Unraveling MCL biology to understand resistance and identify vulnerabilities
Clémentine Sarkozy, Benoît Tessoulin, David Chiron · 2024 · Blood
Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
Zhang Ye, Peng Lu, Yan Wen Zhou, Lifei Zhang · 2021 · PeerJ
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines
Valentina Restelli, Monica Lupi, Micaela Vagni, Rosaria Chilà, Francesco Bertoni, Giovanna L.M. Damia, Laura Carrassa · 2018 · Targeted Oncology
Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study
Seri Jeong, Yu Jin Park, Woobin Yun, Seung‐Tae Lee, Jong Rak Choi, Cheolwon Suh, Jae‐Cheol Jo, Hee Jeong Cha, Jee‐Yeong Jeong, Hee‐Kyung Chang et al. · 2020 · Scientific Reports
Grass carp (Ctenopharyngodon idella) NIK up-regulates the expression of IL-8 by activating the NF-κB canonical pathway
Zhiqing Feng, Tingting Yu, Miaomiao Li, Jihuan Hu, Hongying Zhang, Xiaowen Xu, Xuechun Zhu, Huiling Mao, Chengyu Hu · 2024 · Fish & Shellfish Immunology
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma
Heejae Kang, Lisa M. Maurer, Jing Cheng, Mei Smyers, Linda R. Klei, Dong Hu, Juliana H. Azambuja, Marcelo J. Murai, Ahmed S.A. Mady, Ejaz Ahmad et al. · 2025 · Journal of Clinical Investigation
CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma
Serene Xavier, Vivian T. Nguyen, Vishal Khairnar, An T. Phan, Lu Yang, Michael S. Nelson, Ravi Prakash Shukla, Jinhui Wang, Aimin Li, Huimin Geng et al. · 2025 · Nature Communications
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia
Hao Sun, Romanos Sklavenitis‐Pistofidis, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, John M. Hatcher, Maria Luisa Guerrera, Amanda Kofides, Andres Ramirez‐Gamero, Abigail L. Peachey et al. · 2026 · Blood
Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Joshua P. Plotnik, Adam E. Richardson, Haopeng Yang, Estela Rojas, Velitchka Bontcheva, Colleen Dowell, Sydney Parsons, Ashley Wilson, Vida Ravanmehr, Christine Will et al. · 2024 · Molecular Cancer Therapeutics
Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
Ziduo Li, Edward Abadir, Kenneth Lee, Candice Julie Clarke, Christian Edward Bryant, Wendy A. Cooper, Geoffrey A. Pietersz, James Favaloro, Pablo A. Silveira, Derek N.J. Hart et al. · 2020 · Clinical & Translational Immunology
RelB contributes to the survival, migration and lymphomagenesis of B cells with constitutively active CD40 signaling
Laura B. Kuhn, Stefanie Valentin, Kristina Stojanović, Daniel C. Strobl, Tea Babushku, Yan Wang, Ursula Rambold, Laura Scheffler, Sonja Grath, Dorothy John-Robbert et al. · 2022 · Frontiers in Immunology
GSK-J4 Inhibition of KDM6B Histone Demethylase Blocks Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells by Modulating NF-κB Signaling
Laia Sadeghi, Anthony P. H. Wright · 2023 · Cells
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek · 2018 · BMC Cancer
CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia
Ninghan Zhang, Jiawen Xu, Rong Wang, Ting Shuang Pan, Huan-Xin Zhang, Lingling Yin, Yao Yao, Linyan Xu, Shengyun Zhu, Qing‐Yun Wu et al. · 2021 · Journal of Molecular Medicine
MYD88 Mutations and Sensitivity to Ibrutinib Therapy
Y. Lynn Wang · 2018 · Journal of Molecular Diagnostics
The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
Hildo C. Lantermans, Fangxue Ma, Annemieke Kuil, Sanne van Kesteren, Sevtap A. Yasinoglu, Guang Yang, Sara J. Buhrlage, Jinhua Wang, Nathanael S. Gray, Marie José Kersten et al. · 2024 · Leukemia
Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
Xiaoxian Zhao, Juraj Bodo, Ruoying Chen, Lisa M. Durkin, Andrew James Souers, Darren C. Phillips, Eric D. Hsi · 2020 · eJHaem
Molecular deregulation of signaling in lymphoid tumors
Valeria Spina, Lavinia Martuscelli, Davide Rossi · 2015 · European Journal Of Haematology
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
Fu-Lian Qu, Bing Xia, Su Xia Li, Chen Tian, Hong Yang, Qian Li, Ya Fei Wang, Yong Yu, Yi Zhuo Zhang · 2015 · Europe PMC (PubMed Central)
Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma
Venera Kuci Emruli, Roger Olsson, Fredrik Ek, Sara Ek · 2016 · BMC Cancer
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
Pavel Klener · 2020 · Expert Opinion on Therapeutic Targets
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
Joana M. Rodrigues, Anna Porwit‐MacDonald, May Hassan, Sara Ek, Mats Jerkeman · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
Yannick Le Bris, Adeline Normand, Louise Bouard, Audrey Ménard, Céline Bossard, Anne Moreau, Marie C. Béné · 2022 · eJHaem
Novel Agents in Mantle Cell Lymphoma
Anita Ashok Kumar · 2015 · Current Oncology Reports
Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy
Noraidah Masir, Ariz Akhter, Tariq Roshan, Chandramaya Sabrina Florence, Faridah Abdul‐Rahman, Nor Rafeah Tumian, Kean Chang Phang, Ghaleb Elyamany, Meer‐Taher Shabani‐Rad, Adnan Mansoor · 2019 · Journal of Clinical Pathology
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment
Viktoria Fuhr, Ehsan Vafadarnejad, Oliver Dietrich, Panagiota Arampatzi, Angela Riedel, Antoine‐Emmanuel Saliba, Andreas Rosenwald, Hilka Rauert‐Wunderlich · 2021 · International Journal of Molecular Sciences
Targeting paracaspase1 (MALT1) for cancer therapy: Updated progress and study on structure-activity relationships (SARs)
Yinglong Li, Yanyun Hong, Jianye Zhang, Shan Xu · 2025 · European Journal of Medicinal Chemistry
Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling
Evan A. Mulligan, Susan J. Tudhope, Jill E. Hunter, Arabella E. G. Clift, Sarah L. Elliott, Geoffrey P. Summerfield, Jonathan Peter Wallis, Chris J. Pepper, Barabara Durkacz, Stephany Jane Veuger et al. · 2023 · Cancers
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications
Amatta Mirandari, Helen Parker, Margaret Ashton‐Key, Benjamin Stevens, Renata J. Walewska, Κώστας Σταματόπουλος, Dean J. Bryant, David Graham Oscier, Jane Gibson, Jonathan C. Strefford · 2024 · Exploration of Targeted Anti-tumor Therapy
Cyclin D1 transcriptional activation in MCL
Sı́lvia Beà · 2014 · Blood
Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways
Xinyu Dong, Shujun Tang, Miaohong Chen, Qiuni Chen, Yifan Wang, Yuye Shi, Yuan Deng, Yue Chen, Zhengmei He, Liang Yu et al. · 2026 · Annals of Hematology
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma
John Sharp, Arwa Y. Shana’ah, Timothy J. Voorhees, David Alan Bond, Yazeed Sawalha, Audrey M. Sigmund, Walter G. Hanel, Lalit Sehgal, Lapo Alinari, Robert A. Baiocchi et al. · 2025 · Journal of the National Comprehensive Cancer Network
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop
Brad S. Kahl, Martin H. Dreyling, Leo I. Gordon, Leticia Quintanilla‐Martínez, Eduardo M. Sotomayor · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
Emerging role of SOX11 in mantle cell lymphoma
Sara Ek, Venera Kuci Emruli, Lena Nordström, Mats Jerkeman · 2015 · Blood and Lymphatic Cancer Targets and Therapy
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia
Rupal Tripathi, Eriong Lee‐Vergés, Morihiro Higashi, Neus Giménez, Laia Rosich, Mònica López‐Guerra, Dolors Colomer · 2017 · Expert Opinion on Drug Discovery
Therapeutic Targets in Chronic Lymphocytic Leukemia
Luca Laurenti, Dimitar G. Efremov · 2020 · Cancers
Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
Shuozi Liu, Ping Yang, Lingli Wang, Chunyuan Li, Weilong Zhang, Jing Wang, Hongmei Jing · 2022 · Annals of Translational Medicine
Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma
Aorong Shi, Fen Yun, Lin Shi, Xia Liu, Yongfeng Jia · 2024 · Annals of Medicine
Novel insights into the disease dynamics of B‐cell lymphomas in the Genomics Era
Fong Chun Chan, Emilia L. Lim, Robert Kridel, Christian Steidl · 2018 · The Journal of Pathology
Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop
Brad S. Kahl, Leo I. Gordon, Martin H. Dreyling, Randy D. Gascoyne, Eduardo M. Sotomayor · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer
Maria Elena Carazzolo, Alessia Moioli, Carlo Visco · 2025 · Journal of Clinical Medicine
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
Sieun Yang, Jihye Oh, Soo-Yeon Hwang, Jihye Paik, Inah Hwang · 2026 · Drug Resistance Updates
Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance
Guoxin Hou, Zhimin Lu, Dongqiang Zeng, Qican Chen, Subing Cheng, Binbin Song · 2025 · Carcinogenesis
Optimizing therapy for mantle cell lymphoma
Peter Martin · 2017 · Hematology
Venetoclax for the treatment of mantle cell lymphoma
Victor S. Lin, Mary Ann Anderson, David C.S. Huang, Andrew Warwick Roberts, John Francis Seymour, Constantine Si Lun Tam · 2019 · Annals of Lymphoma
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma
Hong Zhou, Yang Li, Qingxiu Dang, Jianfei Huang, Yuehua Cheng, Yaping Zhang, Wenyu Shi · 2020 · Cancer Biology & Therapy
Identification of Tensin-3 as a MALT1 substrate that controls B cell adhesion and lymphoma dissemination
Mélanie Juilland, Nagham Alouche, Ivana Ubezzi, Montserrat Gonzalez, Harun‐Or Rashid, Léonardo Scarpellino, Tabea Erdmann, Michael Grau, Georg Lenz, Sanjiv A. Luther et al. · 2023 · Proceedings of the National Academy of Sciences
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma
Laura Jacobs, Stefan Habringer, Jolanta Slawska, Katharina Huber, Elke Hauf, Zhoulei Li, Yosef Refaeli, Markus Schwaiger, Martina Rudelius, Axel Karl Walch et al. · 2017 · Oncotarget
Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma
Russell J.H. Ryan, Ryan A. Wilcox · 2019 · Hematology/Oncology Clinics of North America
Non-coding NFKBIZ 3′ UTR mutations promote cell growth and resistance to targeted therapeutics in diffuse large B-cell lymphoma
Sarah E. Arthur, Jie Gao, Shannon Healy, Christopher K. Rushton, Nicole Thomas, Laura K. Hilton, Kostiantyn Dreval, Jeffrey S. Tang, Miguel Alcaide, Razvan Cojocaru et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma
Francesca Maria Quaglia, Simona Gambino, Marilisa Galasso, Maria Carmela Vegliante, Carlo Visco, Maria Teresa Scupoli · 2025 · Cell Communication and Signaling
Rationnel et modalités de prescription de l’ibrutinib dans les hémopathies lymphoïdes B
Aurore Dougé, Aurélie Ravinet, Jacques‐Olivier Bay, Olivier Tournilhac, Romain Guièze, Richard Lemal · 2016 · Bulletin du Cancer
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
Rory McCulloch, Toby Andrew Eyre, Simon A. Rule · 2020 · Hematology/Oncology Clinics of North America
Natural Compound Dioscin Targeting Multiple Cancer Pathways through its High Affinity Binding to B Cell Lymphoma-2
Shweta Gulia, Prakash Chandra, Asmita Das · 2024 · Current Computer - Aided Drug Design
Using genomic data for selecting the treatment of lymphoma patients
Connie Lee Batlevi, Gunjan L. Shah, Christopher J. Forlenza, Andrew M. Intlekofer · 2019 · Current Opinion in Hematology
Overview: A New Era of Cancer Genomics in Lymphoid Malignancies
Shinsuke Iida · 2015 · Oncology
Immunomodulatory agents in mantle cell lymphoma
Kieron M. Dunleavy · 2016 · The Lancet Oncology
Mouse model of MYD88L265P-dependent DLBCL
Siegfried Janz · 2016 · Blood
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress
Khaoula Ben Younes, Simon Body, Élodie Costé, Pierre‐Julien Viailly, Hadjer Miloudi, Clémence Coudre, Fabrice Jardin, Fatma Ben Aissa‐Fennira, Brigitte Sola · 2017 · BMC Cancer
Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
Irene López‐Oreja, Heribert Playà-Albinyana, Fabián Arenas, Mònica López‐Guerra, Dolors Colomer · 2021 · Cancers
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance
Xiaosheng Wu, Kevin E. Nowakowski, Jithma P. Abeykoon, Michelle K. Manske, Mary J. Stenson, Michael Timm, Curtis A. Hanson, Daniel L. Van Dyke, Surendra Dasari, Thomas Elmer Witzig · 2021 · European Journal Of Haematology
Mature B‐ and T‐cell neoplasms and Hodgkin lymphoma
Reiner Siebert, Sietse Aukema · 2015 · Wiley eBooks
Targeting NF ‐κB in Oncology, an Untapped Therapeutic Potential
Matko Kalac · 2023
Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Tímár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics et al. · 2025 · The Journal of Pathology
Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers
Daphne J. F. Kluitmans, Janneke J. T. M. Melis, Esmee van den Bossche, Jacob Ytsma, Jeroen A.D.M. de Roos, Oscar P. J. van Linden, Yvonne Grobben, Jeffrey J. Kooijman, Guido J.R. Zaman · 2025 · Frontiers in Oncology
[Advances of aberrant signaling pathways and related targeting drugs in B cell non- Hodgkin lymphoma].
Chuanhe Jiang, Jianmin Wang · 2015 · PubMed Central
High expression of NF-κB inducing kinase in the bulge region of hair follicle induces tumor
Weisong Duan, Shengmin Guo, Huang Huai-peng, Yunyun Tian, Zhongyao Li, Yue Bi, Le Yi, Mengjie Cao, Moran Guo, Yakun Liu et al. · 2023 · Immunobiology
Reappraising the timing of transplant for indolent non-Hodgkin lymphomas
Saveria Capria, Walter Barberi, Salvatore Perrone, Antonietta Ferretti, Adriano Salaroli, Giorgia Annechini, Gianna Maria D’Elia, Robin Foà, Alessandro Pulsoni · 2016 · Expert Review of Hematology